Oxcarbazepine Suspension
Product Images NDC 62135-841

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 62135-841). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Oxycarbazepine Oral Suspension Figure 1)

An instructional illustration showing a hand holding a bottle with a cap, shaking it side to side. The image likely demonstrates the proper way to shake a medication suspension bottle before use.*

FDA Label Image

Image Description (Oxycarbazepine Oral Suspension Figure 2)

An instructional diagram showing a hand pressing a syringe or dropper straight down into the opening of a bottle, with a downward arrow indicating the direction of insertion. The image illustrates a step in measuring or drawing liquid medication from the bottle.*

FDA Label Image

Image Description (Oxycarbazepine Oral Suspension Figure 3)

An instructional illustration showing a hand holding and moving a dosing syringe up and down while attached to the top of an oral suspension bottle, demonstrating how to draw medication from the bottle using the syringe.*

FDA Label Image

Image Description (Oxycarbazepine Oral Suspension Figure 4)

An instructional illustration showing a child using an oral dosing syringe to take liquid medication, and a hand measuring medication with a syringe above a measuring cup. The image depicts the proper method for administering oral suspension medication using a syringe.*

FDA Label Image

Image Description (Oxycarbazepine Oral Suspension Graph 1)

A Kaplan-Meier survival curve chart showing exit rates over time from Day 2 to Day 11. Two treatment groups are compared: Oxcarbazepine (solid line) and Placebo (dashed line). The chart includes a log-rank test p-value of 0.0001, indicating statistical comparison between groups.*

FDA Label Image

Image Description (Oxycarbazepine Oral Suspension Graph 2)

A Kaplan-Meier survival curve graph showing seizure rate over time (days from first dose to first seizure) comparing two treatment groups: Oxcarbazepine and Placebo. The graph includes a log-rank test p-value of 0.046, indicating a statistical comparison between the groups.*

FDA Label Image

Image Description (Oxycarbazepine Oral Suspension Graph 3)

A Kaplan-Meier survival curve comparing time to exit (in days) between two treatment groups labeled 'HIGH' and 'LOW'. The graph includes an exit rate on the vertical axis and shows a statistically significant difference between groups with a log-rank test p-value of 0.0001.*

FDA Label Image

Image Description (Oxycarbazepine Oral Suspension Graph 4)

A Kaplan-Meier curve graph depicting exit rates over time in days for two treatment groups labeled HIGH and LOW. The graph includes a log-rank test with a p-value of 0.0001, indicating a statistical comparison between the survival distributions of the two groups.*

FDA Label Image

Image Description (Oxycarbazepine Oral Suspension Label)

Label for Oxcarbazepine Oral Suspension USP 300 mg/5 mL in a 250 mL bottle by Chartwell RX. The label includes instructions to shake well before use and storage guidelines, indicating it requires a prescription (Rx Only). It features the NDC number 62135-841-54 and a barcode.*

FDA Label Image

Image Description (Oxycarbazepine Oral Suspension Structure)

Chemical structure of oxcarbazepine, showing a dibenzazepine ring system with a ketone and an amide group attached.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.